Fractyl Health, Inc. GUTS
0.85 USD -0.03 (-3.48%)
Nov 12, 2026, 2:22 PM EST
0.8292 Day range 0.905
0.80 52-week range 29.34
- YTD
- -96.78%
- 1 year
- -93.73%
News
defenseworld.net Fractyl Health, Inc. (NASDAQ:GUTS) Stock Has Consensus Price Target of $50.25 According to Brokerages Shares of Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are presently covering the company, Marketbeat…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
globenewswire.com Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel…
benzinga.com Fractyl Health Expands Revita Patent Portfolio Ahead Of Planned FDA De Novo Submission Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today…
benzinga.com Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027Workforce…- benzinga.com Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39 Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and lowers the price target from $96 to $39.
benzinga.com Morgan Stanley Maintains Equal-Weight on Fractyl Health, Lowers Price Target to $4 Morgan Stanley analyst Michael Ulz maintains Fractyl Health (NASDAQ:GUTS) with a Equal-Weight and lowers the price target from $24 to $4.
benzinga.com Crude Oil Jumps 3%; Citizens Financial Earnings Top Views U.S. stocks fell Friday, led by Nasdaq’s 1.86% drop; energy rose, communication services sank. Oil topped $100 as CFG beat earnings estimates.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics…
benzinga.com Why Fractyl Health Stock Is Sinking Friday Fractyl Health (GUTS) stock sank 50% despite positive REMAIN-1 trial results as class action lawsuit concerns weigh on investors.
benzinga.com Dow Surges 250 Points; M&T Bank Posts Upbeat Q3 Earnings U.S. stocks mixed: Dow +0.48%, Nasdaq -0.65%, S&P -0.05%. Energy rose, tech fell, and M&T Bank beat Q3 estimates; oil eased, gold gained.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock…
- benzinga.com Fractyl Health’s REMAIN-1 Study Meets Six-Month Co-Primary Endpoint With High Statistical Significance; Demonstrates 80% Retention Of GLP-1 Induced Weight Loss Vs 67% For Sham REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham32% of Revita®…
benzinga.com Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 71.93 percent increase over losses of…
benzinga.com Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars Fractyl Health reported one-year REMAIN-1 data showing Revita reduced weight regain after GLP-1 therapy with favorable safety results.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences…
benzinga.com Fractyl Health Announces One-Year Results From Its REMAIN-1 Midpoint Cohort; Results Reinforce Potential Of Revita DMR System To Become First Durable Therapy For Post-GLP-1 Weight Maintenance Key Findings:Dose-dependent durability confirmed at one year: In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40%…- benzinga.com HC Wainwright & Co. Reiterates Buy on Fractyl Health, Maintains $8 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Fractyl Health (NASDAQ:GUTS) with a Buy and maintains $8 price target.
- benzinga.com Fractyl Health Announces 1-Yr Results From Open-Label REVEAL-1 Cohort; Participants Retained ~78% Of GLP-1 Induced Total Body Weight Loss One Year After Discontinuation And Single Revita Procedure Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure5.3% mean weight change observed with Revita (n=15); published…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Fractyl Health Q1 2026 Earnings Call: Complete Transcript 
benzinga.com Fractyl Health Q1 EPS $0.06 Beats $(0.16) Estimate Fractyl Health (NASDAQ:GUTS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.16) by 137.5 percent. This is a 112.24 percent increase over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com Fractyl Health Receives Clinical Trial Application Authorization In Netherlands To Initiate Phase 1/2 First-in-human Study Of RJVA-001, Expects To Start Dosing And Report Preliminary Data In 2H of 2026 Authorization advances Fractyl Health to a dual clinical-stage company, with Revita in pivotal development for post-GLP-1 weight maintenance and Rejuva entering first-in-human studies for type 2…- benzinga.com HC Wainwright & Co. Reiterates Buy on Fractyl Health, Maintains $8 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Fractyl Health (NASDAQ:GUTS) with a Buy and maintains $8 price target.
benzinga.com Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know Fractyl Health's shares jumped 20.9% after hours following its Q4 2025 results and new weight-maintenance data from the REMAIN-1 Midpoint Cohort.- benzinga.com Fractyl Health Q4 EPS $(0.07) Beats $(0.19) Estimate Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.19) by 63.73 percent. This is a 86.54 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 24, 2026
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Fractyl Health Completes Participant Randomization In REMAIN-1 Pivotal Cohort Evaluating Revita For Weight Maintenance Following GLP-1 Therapy Discontinuation Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026Company reiterates cash runway guidance into early 2027, beyond…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Morgan Stanley Downgrades Fractyl Health to Equal-Weight, Lowers Price Target to $2 Morgan Stanley analyst Michael Ulz downgrades Fractyl Health (NASDAQ:GUTS) from Overweight to Equal-Weight and lowers the price target from $8 to $2.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product Fractyl Health stock plunged after the company signaled a possible FDA path change for its Revita device, despite trial data showing weight maintenance and metabolic benefits.
benzinga.com Crude Oil Surges 3%; Caterpillar Shares Gain After Q4 Results - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com US Stocks Mixed; Tesla Posts Upbeat Q4 Earnings - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Fractyl Health Announces 6-Month Randomized Results From Ongoing REMAIN-1 Midpoint Cohort, Blinded, Sham-Controlled Study Evaluating Revita For Weight Maintenance Following GLP-1 Drug Discontinuation Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and…
- benzinga.com Fractyl Health Outlines Its Strategic Outlook For 2026, Highlighting Anticipated Clinical And Regulatory Milestones Across Its Revita And Rejuva Programs, Cash Balance Of $85.6M Is Expected To Provide Cash Runway Through Early 2027 RevitaIn 2026, the Company plans to advance Revita through a series of important clinical and regulatory milestones, building on continued progress across the REVEAL-1, REMAIN-1 Midpoint, and…
benzinga.com Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - benzinga.com Fractyl Health Calls All 17,063,073 Warrants For Cancellation For Cash: Exercise At $1.05, If Fully Exercised Could Raise ~$17.9M Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pioneering pattern-breaking approaches that treat root causes of obesity and type 2…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy.- benzinga.com HC Wainwright & Co. Reiterates Buy on Fractyl Health, Maintains $8 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Fractyl Health (NASDAQ:GUTS) with a Buy and maintains $8 price target.
- benzinga.com Fractyl Health Announces 6-Month Results From Open-Label REVEAL-1 Cohort; Upcoming Randomized 6-Month REMAIN-1 Midpoint Cohort Data Expected In January 2026 Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment1.5% mean weight change observed with…
- benzinga.com Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $8 Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $6 to $8.
- benzinga.com Earnings Scheduled For November 12, 2025